TY - JOUR AU - Huxley, R. AU - Barzi, F. AU - Woodward, M. PY - 2006 DA - 2006// TI - Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies JO - BMJ VL - 332 UR - https://doi.org/10.1136/bmj.38678.389583.7C DO - 10.1136/bmj.38678.389583.7C ID - Huxley2006 ER - TY - JOUR AU - Morrish, N. J. AU - Wang, S. L. AU - Stevens, L. K. AU - Fuller, J. H. AU - Keen, H. PY - 2001 DA - 2001// TI - Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes JO - Diabetologia VL - 44 UR - https://doi.org/10.1007/PL00002934 DO - 10.1007/PL00002934 ID - Morrish2001 ER - TY - JOUR AU - Turner, R. C. AU - Millns, H. AU - Neil, H. A. AU - Stratton, I. M. AU - Manley, S. E. AU - Matthews, D. R. PY - 1998 DA - 1998// TI - Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) JO - BMJ VL - 316 UR - https://doi.org/10.1136/bmj.316.7134.823 DO - 10.1136/bmj.316.7134.823 ID - Turner1998 ER - TY - JOUR AU - Nissen, S. E. AU - Wolski, K. PY - 2007 DA - 2007// TI - Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes JO - N Engl J Med VL - 356 UR - https://doi.org/10.1056/NEJMoa072761 DO - 10.1056/NEJMoa072761 ID - Nissen2007 ER - TY - JOUR AU - Rao, A. D. AU - Kuhadiya, N. AU - Reynolds, K. AU - Fonseca, V. A. PY - 2008 DA - 2008// TI - Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies JO - Diabetes Care VL - 31 UR - https://doi.org/10.2337/dc08-0167 DO - 10.2337/dc08-0167 ID - Rao2008 ER - TY - JOUR AU - Meinert, C. L. AU - Knatterud, G. L. AU - Prout, T. E. AU - Klimt, C. R. PY - 1970 DA - 1970// TI - A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results JO - Diabetes VL - 19 ID - Meinert1970 ER - TY - JOUR AU - Johnson, J. A. AU - Majumdar, S. R. AU - Simpson, S. H. AU - Toth, E. L. PY - 2002 DA - 2002// TI - Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes JO - Diabetes Care VL - 25 UR - https://doi.org/10.2337/diacare.25.12.2244 DO - 10.2337/diacare.25.12.2244 ID - Johnson2002 ER - TY - JOUR AU - Evans, J. M. AU - Ogston, S. A. AU - Emslie-Smith, A. AU - Morris, A. D. PY - 2006 DA - 2006// TI - Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin JO - Diabetologia VL - 49 UR - https://doi.org/10.1007/s00125-006-0176-9 DO - 10.1007/s00125-006-0176-9 ID - Evans2006 ER - TY - JOUR AU - Klamann, A. AU - Sarfert, P. AU - Launhardt, V. AU - Schulte, G. AU - Schmiegel, W. H. AU - Nauck, M. A. PY - 2000 DA - 2000// TI - Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide) JO - Eur Heart J VL - 21 UR - https://doi.org/10.1053/euhj.1999.1999 DO - 10.1053/euhj.1999.1999 ID - Klamann2000 ER - TY - JOUR AU - Zeller, M. AU - Danchin, N. AU - Simon, D. AU - Vahanian, A. AU - Lorgis, L. AU - Cottin, Y. PY - 2010 DA - 2010// TI - Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction JO - J Clin Endocrinol Metab VL - 95 UR - https://doi.org/10.1210/jc.2010-0449 DO - 10.1210/jc.2010-0449 ID - Zeller2010 ER - TY - STD TI - U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry Diabetes Mellitus — Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. 2008. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed July 9, 2014. UR - http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf ID - ref11 ER - TY - JOUR AU - Scirica, B. M. AU - Bhatt, D. L. AU - Braunwald, E. AU - Steg, P. G. AU - Davidson, J. AU - Hirshberg, B. PY - 2013 DA - 2013// TI - Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus JO - N Engl J Med VL - 369 UR - https://doi.org/10.1056/NEJMoa1307684 DO - 10.1056/NEJMoa1307684 ID - Scirica2013 ER - TY - JOUR AU - White, W. B. AU - Cannon, C. P. AU - Heller, S. R. AU - Nissen, S. E. AU - Bergenstal, R. M. AU - Bakris, G. L. PY - 2013 DA - 2013// TI - Alogliptin after acute coronary syndrome in patients with type 2 diabetes JO - N Engl J Med VL - 369 UR - https://doi.org/10.1056/NEJMoa1305889 DO - 10.1056/NEJMoa1305889 ID - White2013 ER - TY - STD TI - White W. Results from EXAMINE. Oral presentation at EASD 2013. http://www.cardiotimes.com/documents/powerpoints/SLI064.ppt. Accessed May 26, 2015. UR - http://www.cardiotimes.com/documents/powerpoints/SLI064.ppt ID - ref14 ER - TY - JOUR AU - Scirica, B. M. AU - Braunwald, E. AU - Raz, I. AU - Cavender, M. A. AU - Morrow, D. A. AU - Jarolim, P. PY - 2014 DA - 2014// TI - Heart Failure, Saxagliptin and Diabetes Mellitus: Observations from the SAVOR - TIMI 53 Randomized Trial JO - Circulation VL - 130 UR - https://doi.org/10.1161/CIRCULATIONAHA.114.010389 DO - 10.1161/CIRCULATIONAHA.114.010389 ID - Scirica2014 ER - TY - JOUR AU - Deacon, C. F. AU - Holst, J. J. PY - 2010 DA - 2010// TI - Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes JO - Expert Opin Investig Drugs VL - 19 UR - https://doi.org/10.1517/13543780903463862 DO - 10.1517/13543780903463862 ID - Deacon2010 ER - TY - JOUR AU - Scheen, A. J. PY - 2011 DA - 2011// TI - Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation) JO - Expert Opin Drug Metab Toxicol VL - 7 UR - https://doi.org/10.1517/17425255.2011.628986 DO - 10.1517/17425255.2011.628986 ID - Scheen2011 ER - TY - JOUR AU - Johansen, O. E. AU - Neubacher, D. AU - Eynatten, M. AU - Patel, S. AU - Woerle, H. J. PY - 2012 DA - 2012// TI - Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme JO - Cardiovasc Diabetol VL - 11 UR - https://doi.org/10.1186/1475-2840-11-3 DO - 10.1186/1475-2840-11-3 ID - Johansen2012 ER - TY - JOUR AU - Ceriello, A. AU - Sportiello, L. AU - Rafaniello, C. AU - Rossi, F. PY - 2014 DA - 2014// TI - DPP-4 inhibitors: pharmacological differences and their clinical implications JO - Expert Opin Drug Saf VL - 13 UR - https://doi.org/10.1517/14740338.2014.944862 DO - 10.1517/14740338.2014.944862 ID - Ceriello2014 ER - TY - JOUR AU - Frederich, R. AU - Alexander, J. H. AU - Fiedorek, F. T. AU - Donovan, M. AU - Berglind, N. AU - Harris, S. PY - 2010 DA - 2010// TI - A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes JO - Postgrad Med VL - 122 UR - https://doi.org/10.3810/pgm.2010.05.2138 DO - 10.3810/pgm.2010.05.2138 ID - Frederich2010 ER - TY - JOUR AU - Williams-Herman, D. AU - Engel, S. S. AU - Round, E. AU - Johnson, J. AU - Golm, G. T. AU - Guo, H. PY - 2010 DA - 2010// TI - Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes JO - BMC Endocr Disord VL - 10 UR - https://doi.org/10.1186/1472-6823-10-7 DO - 10.1186/1472-6823-10-7 ID - Williams-Herman2010 ER - TY - JOUR AU - Schweizer, A. AU - Dejager, S. AU - Foley, J. E. AU - Couturier, A. AU - Ligueros-Saylan, M. AU - Kothny, W. PY - 2010 DA - 2010// TI - Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population JO - Diabetes Obes Metab VL - 12 UR - https://doi.org/10.1111/j.1463-1326.2010.01215.x DO - 10.1111/j.1463-1326.2010.01215.x ID - Schweizer2010 ER - TY - JOUR AU - Engel, S. S. AU - Golm, G. T. AU - Shapiro, D. AU - Davies, M. J. AU - Kaufman, K. D. AU - Goldstein, B. J. PY - 2013 DA - 2013// TI - Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis JO - Cardiovasc Diabetol VL - 12 UR - https://doi.org/10.1186/1475-2840-12-3 DO - 10.1186/1475-2840-12-3 ID - Engel2013 ER - TY - JOUR AU - Dzau, V. AU - Braunwald, E. PY - 1991 DA - 1991// TI - Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement JO - Am Heart J VL - 121 UR - https://doi.org/10.1016/0002-8703(91)90694-D DO - 10.1016/0002-8703(91)90694-D ID - Dzau1991 ER - TY - JOUR AU - Lee, S. J. AU - Leipzig, R. M. AU - Walter, L. C. PY - 2013 DA - 2013// TI - Incorporating lag time to benefit into prevention decisions for older adults JO - JAMA VL - 310 UR - https://doi.org/10.1001/jama.2013.282612 DO - 10.1001/jama.2013.282612 ID - Lee2013 ER - TY - STD TI - McMurray J. Vildagliptin shows no adverse effect on ejection fraction in diabetic patients with HF. Presented at the Heart Failure Congress 2013, Lisbon, Portugal, May 25–28, 2013. abstract. ID - ref26 ER - TY - JOUR AU - Monami, M. AU - Dicembrini, I. AU - Mannucci, E. PY - 2014 DA - 2014// TI - Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials JO - Nutr Metab Cardiovasc Dis VL - 24 UR - https://doi.org/10.1016/j.numecd.2014.01.017 DO - 10.1016/j.numecd.2014.01.017 ID - Monami2014 ER - TY - JOUR AU - Wu, S. AU - Hopper, I. AU - Skiba, M. AU - Krum, H. PY - 2014 DA - 2014// TI - Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: Meta-analysis of randomized clinical trials with 55,141 participants JO - Cardiovasc Ther VL - 32 UR - https://doi.org/10.1111/1755-5922.12075 DO - 10.1111/1755-5922.12075 ID - Wu2014 ER - TY - JOUR AU - Zannad, F. AU - Cannon, C. AU - Cushman, W. AU - Bakris, G. AU - Nissen, S. AU - Heller, S. PY - 2014 DA - 2014// TI - Alogliptin in patients with type 2 diabetes after acute coronary syndromes: heart failure outcomes and cardiovascular safety in heart failure patients JO - J Am Coll Cardiol VL - 63 UR - https://doi.org/10.1016/S0735-1097(14)60117-0 DO - 10.1016/S0735-1097(14)60117-0 ID - Zannad2014 ER - TY - JOUR AU - Scheen, A. J. PY - 2015 DA - 2015// TI - Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes JO - Expert Opin Drug Saf VL - 14 UR - https://doi.org/10.1517/14740338.2015.1006625 DO - 10.1517/14740338.2015.1006625 ID - Scheen2015 ER - TY - JOUR AU - Eynatten, M. AU - Gong, Y. AU - Emser, A. AU - Woerle, H. J. PY - 2013 DA - 2013// TI - Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials JO - Cardiovasc Diabetol VL - 12 UR - https://doi.org/10.1186/1475-2840-12-60 DO - 10.1186/1475-2840-12-60 ID - Eynatten2013 ER - TY - JOUR AU - Tricco, A. C. AU - Antony, J. AU - Khan, P. A. AU - Ghassemi, M. AU - Hamid, J. S. AU - Ashoor, H. PY - 2014 DA - 2014// TI - Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis JO - BMJ Open VL - 4 UR - https://doi.org/10.1136/bmjopen-2014-005752 DO - 10.1136/bmjopen-2014-005752 ID - Tricco2014 ER - TY - JOUR AU - Green, J. B. AU - Bethel, M. A. AU - Paul, S. K. AU - Ring, A. AU - Kaufman, K. D. AU - Shapiro, D. R. PY - 2013 DA - 2013// TI - Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease JO - Am Heart J VL - 166 UR - https://doi.org/10.1016/j.ahj.2013.09.003 DO - 10.1016/j.ahj.2013.09.003 ID - Green2013 ER - TY - JOUR AU - Darsalia, V. AU - Ortsater, H. AU - Olverling, A. AU - Darlof, E. AU - Wolbert, P. AU - Nystrom, T. PY - 2013 DA - 2013// TI - The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride JO - Diabetes VL - 62 UR - https://doi.org/10.2337/db12-0988 DO - 10.2337/db12-0988 ID - Darsalia2013 ER - TY - JOUR AU - Nakamura, K. AU - Oe, H. AU - Kihara, H. AU - Shimada, K. AU - Fukuda, S. AU - Watanabe, K. PY - 2014 DA - 2014// TI - DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study JO - Cardiovasc Diabetol VL - 13 UR - https://doi.org/10.1186/s12933-014-0110-2 DO - 10.1186/s12933-014-0110-2 ID - Nakamura2014 ER - TY - JOUR AU - Ott, C. AU - Raff, U. AU - Schmidt, S. AU - Kistner, I. AU - Friedrich, S. AU - Bramlage, P. PY - 2014 DA - 2014// TI - Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes JO - Cardiovasc Diabetol VL - 13 UR - https://doi.org/10.1186/1475-2840-13-19 DO - 10.1186/1475-2840-13-19 ID - Ott2014 ER - TY - JOUR AU - Rosenstock, J. AU - Marx, N. AU - Kahn, S. E. AU - Zinman, B. AU - Kastelein, J. J. AU - Lachin, J. M. PY - 2013 DA - 2013// TI - Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial JO - Diab Vasc Dis Res VL - 10 UR - https://doi.org/10.1177/1479164112475102 DO - 10.1177/1479164112475102 ID - Rosenstock2013 ER - TY - JOUR AU - Marx, N. AU - Rosenstock, J. AU - Kahn, S. E. AU - Zinman, B. AU - Kastelein, J. J. AU - Lachin, J. M. PY - 2015 DA - 2015// TI - Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes: CAROLINA® JO - Diab Vasc Dis Res VL - 12 UR - https://doi.org/10.1177/1479164115570301 DO - 10.1177/1479164115570301 ID - Marx2015 ER - TY - JOUR AU - Gomis, R. AU - Espadero, R. -. M. AU - Jones, R. AU - Woerle, H. J. AU - Dugi, K. A. PY - 2011 DA - 2011// TI - Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo controlled study JO - Diabetes Obes Metab VL - 13 UR - https://doi.org/10.1111/j.1463-1326.2011.01391.x DO - 10.1111/j.1463-1326.2011.01391.x ID - Gomis2011 ER - TY - JOUR AU - Prato, S. AU - Barnett, A. H. AU - Huisman, H. AU - Neubacher, D. AU - Woerle, H. J. AU - Dugi, K. A. PY - 2011 DA - 2011// TI - Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial JO - Diabetes Obes Metab VL - 13 UR - https://doi.org/10.1111/j.1463-1326.2010.01350.x DO - 10.1111/j.1463-1326.2010.01350.x ID - Prato2011 ER - TY - JOUR AU - Taskinen, M. R. AU - Rosenstock, J. AU - Tamminen, I. AU - Kubiak, R. AU - Patel, S. AU - Dugi, K. A. PY - 2011 DA - 2011// TI - Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study JO - Diabetes Obes Metab VL - 13 UR - https://doi.org/10.1111/j.1463-1326.2010.01326.x DO - 10.1111/j.1463-1326.2010.01326.x ID - Taskinen2011 ER - TY - JOUR AU - Owens, D. R. AU - Swallow, R. AU - Dugi, K. A. AU - Woerle, H. J. PY - 2011 DA - 2011// TI - Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24 week randomised study JO - Diabet Med VL - 28 UR - https://doi.org/10.1111/j.1464-5491.2011.03387.x DO - 10.1111/j.1464-5491.2011.03387.x ID - Owens2011 ER - TY - JOUR AU - Heise, T. AU - Graefe-Mody, E. U. AU - Huttner, S. AU - Ring, A. AU - Trommeshauser, D. AU - Dugi, K. A. PY - 2009 DA - 2009// TI - Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients JO - Diabetes Obes Metab VL - 11 UR - https://doi.org/10.1111/j.1463-1326.2009.01046.x DO - 10.1111/j.1463-1326.2009.01046.x ID - Heise2009 ER - TY - JOUR AU - Forst, T. AU - Uhlig-Laske, B. AU - Ring, A. AU - Ritzhaupt, A. AU - Graefe-Mody, U. AU - Dugi, K. A. PY - 2011 DA - 2011// TI - The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus JO - Diabetes Obes Metab VL - 13 UR - https://doi.org/10.1111/j.1463-1326.2011.01386.x DO - 10.1111/j.1463-1326.2011.01386.x ID - Forst2011 ER - TY - JOUR AU - Singh-Franco, D. AU - McLaughlin-Middlekauff, J. AU - Elrod, S. AU - Harrington, C. PY - 2012 DA - 2012// TI - The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis JO - Diabetes Obes Metab VL - 14 UR - https://doi.org/10.1111/j.1463-1326.2012.01586.x DO - 10.1111/j.1463-1326.2012.01586.x ID - Singh-Franco2012 ER - TY - JOUR AU - Forst, T. AU - Uhlig-Laske, B. AU - Ring, A. AU - Graefe-Mody, U. AU - Friedrich, C. AU - Herbach, K. PY - 2010 DA - 2010// TI - Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes JO - Diabet Med VL - 27 UR - https://doi.org/10.1111/j.1464-5491.2010.03131.x DO - 10.1111/j.1464-5491.2010.03131.x ID - Forst2010 ER - TY - JOUR AU - Rauch, T. AU - Graefe-Mody, U. AU - Deacon, C. F. AU - Ring, A. AU - Holst, J. J. AU - Woerle, H. J. PY - 2012 DA - 2012// TI - Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus JO - Diabetes Ther VL - 3 UR - https://doi.org/10.1007/s13300-012-0010-y DO - 10.1007/s13300-012-0010-y ID - Rauch2012 ER -